Caris Life Sciences to Present Data on Clinical Benefit of Caris Molecular Intelligence at 2016 Gastrointestinal Cancers Symposium

Data Provides Insights on Precision Cancer Care in Rare and Aggressive Malignancies

 IRVING, Tex., Jan. 21, 2016 Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today that it will present five data abstracts at the 2016 Gastrointestinal Cancers Symposium, January 21-23, 2016 in San Francisco, Calif.

Each of the five studies being presented used Caris Molecular Intelligence® (CMI), the company’s panomic, comprehensive, and patented tumor profiling product, to facilitate biomarker identification and molecular characterization of gastrointestinal cancers across different subtypes and age groups. Because Caris Molecular Intelligence utilizes multiple advanced technologies to examine DNA, RNA and proteins, investigators were able to gain a better molecular understanding of rare and aggressive malignancies. CMI also informs physicians regarding therapeutic options of potential benefit and also potential lack of benefit, including immunotherapies, targeted therapies and chemotherapies, in patients with different subtypes of gastrointestinal cancers.

Following is a schedule of Caris Life Sciences’ poster presentations:

Title: Tumor profiling of 431 pancreatic tumors from elderly patients
Date and Time: Friday January 22, 12:30 p.m. – 2:00 p.m.
Abstract: 257
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract; Board D3
Authors: Joanne Xiu, Kevin Rakszawski, Sandeep Reddy, Yuxia Jia
Research Partner: Penn State Milton S. Hershey Medical Center

Title: PD-1/PD-L1 expression and molecular associations in HPB malignancies
Date and Time: Friday January 22, 12:30 p.m. – 2:00 p.m.
Abstract: 289
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session B – Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract; Board E13
Authors: Kabir Mody, Rebecca Feldman, Sandeep Reddy, Gina Reynolds, Jessica McMillan, Elizabeth Johnson
Research Partner: Mayo Clinic (Florida)

Title: Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome
Date and Time: Saturday January 23, 12:30 p.m. – 2:00 p.m.
Abstract: 505
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session C – Cancers of the Colon, Rectum, and Anus; Board A18
Authors: Arielle Heeke, Joanne Xiu, Sandeep Reddy, Jiji Jiang, Hongkun Wang, John Marshall, Mohamed Salem
Research Partner:  Lombardi Comprehensive Cancer Center, Georgetown University

Title: Molecular profiling of appendix-derived pseudomyxoma peritonei (PMP)
Date and Time: Saturday January 23, 12:30 p.m. – 2:00 p.m.
Abstract:  571
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session C – Cancers of the Colon, Rectum, and Anus; Board D20
Authors: Elizabeth Gleeson, Rebecca Feldman, Sherri Millis, Beth Mapow, Lynn Mackovick, Sandeep Reddy, Wilbur Bowne
Research Partner: Drexel University College of Medicine

Title: TOPO1 expression in primary and metastatic GI cancers
Date and Time: Saturday January 23, 12:30 p.m. – 2:00 p.m.
Abstract:  643
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session C – Cancers of the Colon, Rectum, and Anus; Board H4
Authors: Michael Castro, Rebecca Feldman, Sandeep Reddy
Research Partner: Personalized Cancer Medicine, PLLC

About Caris Life Sciences®
Founded by David D. Halbert in 2008, Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling product, with more than 80,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival.  The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

Media Inquiries:
Caris Life Sciences Media Relations & Corporate Affairs
CorpComm@carisls.com

David Patti
JFK Communications
dpatti@jfkhealth.com
609-456-0822

Download PDF Version - Caris Life Sciences to Present Data on Clinical Benefit of Caris Molecular Intelligence at 2016 Gastrointestinal Cancers Symposium